Suicide Risk From Weight-Loss Drugs Prompts More EU Questions

Altimmune Jumps 66% After Positive Results for Its Obesity Drug

Long-Time Novo Bull Slashes Stake Citing Weight-Loss Drug Hype

A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs

New ETF Tracks Developers of Obesity Drugs Amid Ozempic Hype

Germany Mulls Obesity Drug Export Ban as EU Confronts Shortage

Novo Shares Rise After Wegovy Demonstrates Heart Benefit in Trial

One Dose of Lilly’s Novel Heart Drug Cut Risk Factors for a Year

Wegovy Study Bolsters Use In Patients With Obesity and Heart Disease

Weight-Loss Drugs Among the Most Sought-After New Corporate Benefits

Novo to Build $6 Billion Plant as Obesity Drug Demand Surges

Asia Markets Under Pressure After Treasuries Slip : Markets Wrap